Cassava Sciences (SAVA) has gone down about 30% since November, the last time I covered it (this article has not been published). The reason for the decline could have been attributed to the data drop ...

Epicrispr Reports Early Clinical Activity and Favorable Safety Profile in First-in-Human Epigenetic Editing Study for FSHD ...

The TouCAHn trial is an open-label, global, Phase 2 study designed to evaluate the efficacy, safety, and pharmacokinetics of atumelnant when ...

CHICAGO--(BUSINESS WIRE)--An open-label extension study of 121 pediatric patients with Tourette syndrome evaluated the safety profile of the investigational drug ecopipam for up to 12-months of ...

Cassava Sciences, which spent 2022 trying to prove the integrity of its Alzheimer’s disease program, is trumpeting a phase 2 win for simufilam in an open-label study—but investors aren’t convinced.

Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Atai Beckley BPL-003 phase IIb open-label extension ...

Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non–Small-Cell Lung Cancer ...

— Results Demonstrated that LYBALVI was Generally Well Tolerated With Stability of Body Weight and Metabolic Profile, and Durable Symptom Control, for Up to Four Years of Treatment — In this global, ...

– Significant decreases in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers associated with skeletal muscle damage– BOULDER, Colo.--(BUSINESS ...